Trials / Completed
CompletedNCT03172624
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
A Phase II Study of Nivolumab Plus Ipilimumab in Patients With Recurrent/Metastatic Salivary Cancers
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out what effects, good and/or bad, treatment with two drugs called nivolumab and ipilimumab have on the participant and salivary cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | nivolumab 3 mg/kg every 2 weeks |
| DRUG | Ipilimumab | ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks) |
Timeline
- Start date
- 2017-05-26
- Primary completion
- 2024-12-18
- Completion
- 2024-12-18
- First posted
- 2017-06-01
- Last updated
- 2025-12-18
- Results posted
- 2025-12-18
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03172624. Inclusion in this directory is not an endorsement.